Ahmedabad, April 28 -- Gujarat has reinforced its status as India's pharmaceutical leader by approving 183 new allopathic drug manufacturing facilities in the fiscal year 2024-25, the highest number since the COVID-19 pandemic.

This surge brings the total number of new allopathic drug plants approved since March 2019 to over 800, underscoring the state's pivotal role in the nation's pharmaceutical landscape.

H.G. Koshia, Commissioner of the Gujarat Food and Drug Control Administration (FDCA), highlighted that these new plants are poised to become operational soon, further bolstering Gujarat's dominance in the sector.

The average investment per plant is estimated at Rs 50 crore, with some companies investing significantly more, leading ...